KOVANAZE
Peakoxymetazoline hydrochloride; tetracaine hydrochloride
NDANASALSPRAY, METERED
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
KOVANAZE (oxymetazoline hydrochloride; tetracaine hydrochloride) is impulses. First approved in 2016.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KOVANAZE is a fixed-dose nasal spray combining oxymetazoline hydrochloride (a sympathomimetic vasoconstrictor) and tetracaine hydrochloride (a topical anesthetic). It reduces nasal blood flow through α1/α2-adrenoceptor agonism while providing local anesthesia, indicated for nasal procedures requiring hemostasis and anesthesia.
LOE Approaching3.9 years to LOE
Product in peak lifecycle with 4 years until loss of exclusivity; brand teams should focus on market defense and potential life-cycle extension strategies.
Mechanism of Action
impulses. Oxymetazoline is an imidazoline derivative with sympathomimetic activity. It is believed to be a mixed α 1 /α 2 -adrenoceptor agonist and, by stimulating adrenergic receptors, it elicits vasoconstriction of dilated arterioles and reduces nasal blood flow.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.